Skip to Content

Pfizer Inc

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation

Pfizer's Diverse Portfolio of Drugs and Vaccines Supports Steady Cash Flows

Business Strategy and Outlook

Pfizer's foundation remains solid, based on strong cash flows generated from a basket of diverse drugs. The company's large size confers significant competitive advantages in developing new drugs. This unmatched heft, combined with a broad portfolio of patent-protected drugs, has helped Pfizer build a wide economic moat around its business.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of PFE so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center